Especially during late perimenopause, when estrogen levels are still unaltered although ovarian failure is impending, a sharp increase of serum FSH levels was associated with an enhanced rate of bone loss and visceral adiposity onset, proposing FSH as a potential key player in osteoporosis and obesity in women across the menopausal transition [171,178]. The gene discussed is BRD2; the disease is osteoporosis.